Featured Research

from universities, journals, and other organizations

Cholesterol-Lowering Drugs Provide Double Protection Against Heart Disease

Date:
July 15, 1999
Source:
American Heart Association
Summary:
Cholesterol-lowering drugs may ward off a secondary complication of high blood cholesterol, according to a report in Circulation: Journal of the American Heart Association.

DALLAS, July 13 -- Cholesterol-lowering drugs may ward off a secondary complication of high blood cholesterol, according to a report in today's Circulation: Journal of the American Heart Association.

Cholesterol-lowering drugs reduce blood cholesterol, which can collect in the blood vessels, triggering a heart attack. New evidence suggests elevated cholesterol also can lead to a remodeling of the blood vessel wall that causes it to constrict, a condition called reduced myocardial vasodilation (MVD). However, the condition seems reversible with cholesterol-lowering treatment, say University of Tokyo researchers.

"Reduced MVD may be an early sign of coronary heart disease, because we were able to identify the condition in individuals with coronary heart disease who did not have extensive fatty deposits, or plaque, in their blood vessel. Our findings suggest that it is vital that this condition be treated in order to avoid a heart attack, and also that cholesterol-lowering drugs can help reverse this remodeling process," says lead author Ikuo Yokoyama, M.D., of the department of cardiovascular medicine at the University of Tokyo.

The researchers found that this reversal was also associated with improvements in blood pressure, both systolic (heart pumping) and diastolic (heart at rest).

"Reversing remodeling may result in a reduction in the development of plaque, which in turn can reduce the risk of a heart attack," says Yokoyama. However, further research is needed to confirm this idea.

The Japanese team did not set out to test the effectiveness of any particular cholesterol-lowering drug in improving blood flow to the heart muscle, and several drugs were used, often in combination.

Yokoyama and his team studied 27 people with high cholesterol, 17 men and 10 women, and compared them to 12 men and 4 women with normal cholesterol levels. The high cholesterol group had an average total cholesterol level of 263 milligrams per deciliter (mg/dl), compared to 197 mg/dl in the second group. There were no other significant differences between the two groups; they were similar in age, gender, body weight, height, blood pressure and smoking habits. Sixteen members of the high-cholesterol group had chest pain and other signs of coronary heart disease, but angiograms (an X-ray of the blood vessel) indicated that most of their blood vessels were normal. Twenty-five of those with high cholesterol were treated with a combination of medications and a low-cholesterol diet, and two by diet alone. The high cholesterol group saw their levels drop to an average of 197 mg/dl during the course of therapy.

The researchers measured myocardial (heart) blood flow using a technique called positron emission tomography (PET). Readings were made when the patients were at rest and when they were given dipyridamole, a drug used to determine how much the blood vessels dilate to allow blood flow. Blood vessels must dilate and constrict to respond to the daily stresses on the heart. The PET test provides a way to test this ability, by stressing the blood vessels and measuring how well they respond. The team measured blood flow again eight to 15 months after medication and/or dietary therapies were given.

Myocardial blood flow at rest as measured by PET was similar in the high-cholesterol patients and those with normal cholesterol levels, both at the beginning and end of the study. However, when people in the two groups were given the dilating drug to test their blood vessel's response, those with high cholesterol had significantly lower blood flow to the heart muscle than the healthy group.

After their course of cholesterol-lowering drug therapy, those with high cholesterol experienced a significant improvement in blood flow to their heart muscle. However, it was still lower than in the group with normal cholesterol levels.

Sixteen of the high-cholesterol patients also had high blood pressure, and five had diabetes, both of which can contribute to the remodeling of coronary blood vessels. When the Japanese team excluded these patients from their analysis, the results indicated that the cholesterol-lowering drugs led to a more complete reversal of MVD, and normalized the blood vessels of those with high cholesterol only.

Researchers say the "inclusion of those with high blood pressure or diabetes" may account for the variation in the response to the therapy.

Co-authors of the paper are Shin-ichi Momomura, M.D.; Tohru Ohtake, M.D.; Katsunori Yonekura, M.D.; Weidong Yang, M.D.; Naoshi Kobayakawa, M.D.; Teruhiko Aoyagi, M.D.; Seiryo Sugiura, M.D.; Nobuhiro Yamada, M.D.;Kuni Ohtomo, M.D.; Yasuhito Sasaki, M.D.; Masao Omata, M.D.; and YoshioYazaki, M.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Cholesterol-Lowering Drugs Provide Double Protection Against Heart Disease." ScienceDaily. ScienceDaily, 15 July 1999. <www.sciencedaily.com/releases/1999/07/990715063346.htm>.
American Heart Association. (1999, July 15). Cholesterol-Lowering Drugs Provide Double Protection Against Heart Disease. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1999/07/990715063346.htm
American Heart Association. "Cholesterol-Lowering Drugs Provide Double Protection Against Heart Disease." ScienceDaily. www.sciencedaily.com/releases/1999/07/990715063346.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins